



Supplemental Figure 1. Binding specificity of anti-DC Nanobodies. Overlay histograms of fluorescence intensity of labeled Nanobodies on immature and LPS-matured bone-marrow derived dendritic cells are shown. Histograms with solid background and dotted line represent binding of Alexa488-labeled control Nanobody BCII10 and histograms with solid line represent binding of Alexa488-labeled Nb-DC1.8 (A, E, I; C, G, K) or Nb-DC2.1 (B, F, J; D, H, L) without pre-incubation (A-D) or after pre-incubation with unlabeled Nb-DC1.8 (E-H) or Nb-DC2.1 (I-L).



Supplemental Figure 2. Binding specificity of grafted Nanobodies. Overlay histograms of fluorescence intensity of labeled Nanobodies on immature bone-marrow derived dendritic cells are shown. Histograms with solid background and dotted line represent binding of Alexa488-labeled control Nanobody BCII10 and histograms with solid line represent binding of Alexa488-labeled Nb-DC1.8 graft (A) or Nb-DC2.1 graft (B) or binding of Alexa488-labeled Nb-DC1.8 (C, E, G) or Nb-DC2.1 (D, F, H) without pre-incubation (C, D) or after pre-incubation with unlabeled Nb-DC1.8 graft (E, F) or Nb-DC2.1 graft (G, H).



Supplemental Figure 3. Binding specificity of anti-DC Nanobodies. Overlay histograms of fluorescence intensity of labeled Nanobodies on CD4⁺ T-cells (A, E), CD8⁺ T-cells (B, F), CD19⁺ B-cells (C, G) and CD11b⁺ myeloid cells (D, H) are shown. Histograms with solid background and dotted line represent binding of Alexa488-labeled control Nanobody BCII10 and histograms with solid line represent binding of Alexa488-labeled Nb-DC1.8 (A-D) or Nb-DC2.1 (E-G).